GDRX NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Goodrx Holdings Inc · Healthcare · Health Information Services

Open interactive chart View report data
Latest close 3.07 USD
3.7% latest week
Weekly setup

Constructive, but selective

The weekly trend is active. Price is 21.2% above the Trend Line and sits at 32.2% of its 52-week range. The latest completed week returned 3.7%, after a 0.7% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks weakly; valuation is inexpensive relative to peers. Options positioning is volatility with 50/100 conviction, while the latest news-sentiment score is 52/100. Near-term considerations: volume confirmation is below normal; earnings are due in 4d.

Setup score 37 out of 100
Latest Close 3.07 USD 31 Jul 2026
1W Return 3.7% latest completed week
4W Return 0.7% short-term follow-through
12W Return 5.1% quarterly tape
Trend Breadth 9.6% 5 of 52 weeks active
Volume Ratio 0.9x vs 13-week average
What is working
  • The trend backdrop is active with a 5-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Next-week expectancy is negative at 41.06% based on similar historical setup states.
  • The share remains more than 20% below its 52-week high.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 3.7% Latest completed week; four-week move 0.7%. Indicator stack 23/76 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 41.06% Historical one-week expectancy contributes to the evidence score when direction is confirmed. Options pressure Volatility 50/100 conviction; expected move 13.2%. News sentiment 52/100 56 relevant articles in the latest sentiment read. Event risk 4d Next report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 21.2% above the Trend Line and sits at 32.2% of its 52-week range. The latest completed week returned 3.7%, after a 0.7% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.9x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.5212-week average 0.27

12-week confirmation

Trend active5/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.52Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 0.7% over four weeks, 5.1% over 12 weeks, and -32.2% over one year. The current trend has remained active for 5 consecutive weeks.

Performance by holding period

1W3.7%
4W0.7%
12W5.1%
26W35.2%
52W-32.2%
Active trend streak5 weeks
Active weeks in one year5
Trend breadth9.6%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure1.37Latest activity-pressure read.
Pressure change17.2%Four-week change in activity pressure.
Leadership-5.70Latest relative-leadership reading.
RS change62.7%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks weakly; valuation is inexpensive relative to peers.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 94% Model confidence 90%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength79/100Blend of value, momentum, and quality. Underlying universe rank 22; rank 1 is best.
Value81/100Relative valuation strength. Underlying universe rank 20; rank 1 is best.
Quality87/100Profitability and accounting quality. Underlying universe rank 14; rank 1 is best.
Momentum7/100Medium-term price momentum. Underlying universe rank 94; rank 1 is best.
Growth7/100Revenue and earnings growth. Underlying universe rank 94; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Value-quality framework64/100Value and quality alignment from the Sharemaestro SVQF framework.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
48.8x
Price divided by trailing earnings.
Price / sales
1.3x
Market value relative to trailing revenue.
EV / EBITDA
7.5x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
18.7%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
86.6%
Gross profit retained from each unit of revenue.
Operating margin
11.1%
Operating profit retained from revenue.
Free-cash-flow margin
31.0%
Free cash flow generated from revenue.
Return on invested capital
4.2%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-1.2%
Latest one-year revenue growth.
EPS growth
-44.1%
Latest one-year earnings-per-share growth.
Free-cash-flow growth
18.0%
Latest one-year free-cash-flow growth.
Piotroski F-score
6/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
12.7%
Net share repurchases relative to market value.
Shareholder yield
12.7%
Dividend yield plus net buyback yield.
Net debt / EBITDA
1.8x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

GDRX shows volatility options pressure with a 50/100 conviction score, put-call volume ratio of 0.00, expected move of 13.2%, and Sharemaestro trend signal active.

Conviction50/100
Expected move13.2%
Put/call volume0.00
Pressure100
Speculation1
Volatility78
Trend agreement0
Open options detail
Insider activity10 / 10

10 acquisitions and 10 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment52/100

Weighted news tone is neutral across 56 relevant articles.

9 positive · 44 neutral · 3 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings4dNext report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
Options expected move13.2%Nearest-chain priced movement where available.
52-week drawdown-47.2%Distance below the 52-week high.
13-week volatility8.4%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher16 of 269 weeks finished lower.
Best week+21.9%Week of 6 Mar.
Worst week-24.3%Week of 27 Feb.
Latest week+3.7%Week of 31 Jul.

Shape of recent returns

Strong gains12
Modest gains4
Flat weeks1
Modest losses2
Sharp losses7
Recent vol8.4%13-week weekly-return volatility.
Base vol9.6%52-week weekly-return volatility.
Up/down split24/26Count of positive and negative weeks in the 52-week window.
Average skew7.9% / -7.8%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape35/100

Trend, activity pressure, participation, and risk combine to a 35/100 tape read.

 Indicator analysis49/100

Latest 12-week confirmation: trend 5/12, activity pressure 12/12, relative leadership 0/12.

Activity pressure 0.52; No reversal markers Next-Week ExpectancyNegative 41.06%

Next-week expectancy is negative with a 41.06% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors65/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 4; Small Cap Core rank 19 SVQF64/100

Value and quality alignment from the Sharemaestro SVQF framework.

Composite rank 264.0 of 726 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options35/100

GDRX shows volatility options pressure with a 50/100 conviction score, put-call volume ratio of 0.00, expected move of 13.2%, and Sharemaestro trend signal active.

Volatility · Volatility expansion watch · Expected move 13.2% Sentiment52/100

Weighted news tone is neutral across 56 relevant articles.

GDRX|GoodRx Holdings Inc|Price:3.195|Chg%:-0.025 Insiders10 / 10

10 acquisitions and 10 disposals in the latest 180-day insider tape.

 Earnings4d

Next report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20263.07 USD3.7%2.53 USD4.97 USD1.37-5.706.2MOn
24 Jul 20262.96 USD-5.7%2.52 USD5.01 USD1.39-9.954.4MOn
17 Jul 20263.14 USD6.4%2.52 USD5.03 USD1.38-7.684.8MOn
10 Jul 20262.95 USD-3.3%2.50 USD5.05 USD1.27-18.114.1MOn
3 Jul 20263.05 USD8.9%2.50 USD5.08 USD1.17-15.295.7MOn
26 Jun 20262.80 USD5.3%2.49 USD5.10 USD1.14-22.805.4MOff
19 Jun 20262.66 USD0.4%2.49 USD5.12 USD1.19-31.255.7MOff
12 Jun 20262.65 USD0.0%2.49 USD5.13 USD1.24-30.995.2MOff
5 Jun 20262.65 USD-9.2%2.50 USD5.15 USD1.25-30.579.1MOff
29 May 20262.92 USD10.2%2.52 USD5.17 USD1.29-27.959.6MOff
22 May 20262.65 USD9.1%2.53 USD5.19 USD1.25-33.576.4MOff
15 May 20262.43 USD-16.8%2.57 USD5.21 USD1.12-39.127.8MOff
8 May 20262.92 USD14.5%2.62 USD5.22 USD0.99-28.1113.0MOff
1 May 20262.55 USD10.4%2.67 USD5.24 USD0.65-34.817.5MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.